Article Text

other Versions

PDF
Thiazolidinediones and Cardiovascular Outcomes in Type 2 Diabetes
  1. Sonal Singh (sosingh{at}wfubmc.edu)
  1. Wake Forest University School of Medicine, Winston-Salem, NC, United States
    1. Curt D Furberg
    1. Wake Forest University School of Medicine, Winston-Salem, NC, United States

      Abstract

      Patients with type 2 diabetes experience high rates of co-morbid conditions such as hypertension and dyslipidemia that further compound their already increased risk of developing ischemic heart disease (IHD). IHD and hypertension, in turn, represent conditions that are major precursors of congestive heart failure (CHF), adding to the cardiovascular disease (CVD) burden in this patient population. This is reflected in the reported estimate of IHD prevalence in diabetics (approximating 22%)1and the reported 10-year incidence of CHF among elderly patients with newly diagnosed type 2 diabetes (exceeding 50%).2 The American Heart Association and the American Diabetes Association have also noted in a joint scientific statement paper that CVD contributes to more than three-quarters of all death in diabetic patients.3

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.